Karine Rossignol, Smart Immune CEO (Laurent Attias/Smart Immune)

Scoop: Smart Im­mune tar­gets $54M Se­ries A to ad­vance T cell prog­en­i­tor ther­a­py: #Jef­feries23

French biotech Smart Im­mune has raised more than half of its rough­ly €50 mil­lion ($54 mil­lion) tar­get in an on­go­ing Se­ries A round, with an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.